Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19520 | 0.97 | TSHR (0.70) | TSHRIDO1AGXTALDH1A1CA1 | |
| Phosphine SCHEMBL7705717 | 0.95 | TSHR (0.67) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL10660158 | 0.95 | TSHR (0.67) | TSHRIDO1AGXTALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL28406455 | 0.93 | TSHR (0.64) | TSHRIDO1AGXTALDH1A1CA1 | |
| Magnesium Chloride Anhydrous SCHEMBL28406453 | 0.91 | TSHR (0.61) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL344059 | 0.86 | TSHR (0.61) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL71046 | 0.86 | TSHR (0.61) | TSHRIDO1AGXTALDH1A1CA1 | |
| Methylene Chloride SCHEMBL27690292 | 0.84 | TSHR (0.83) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL14947971 | 0.84 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA2 | |
| SCHEMBL25310046 | 0.82 | TSHR (0.56) | TSHRIDO1AGXTALDH1A1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4165037-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | Aligos Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | TSHR 4775/4885IDO1 3030/4885AGXT 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.